NCT02339571 2026-03-19A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaNational Cancer Institute (NCI)Phase 2/3 Active not recruiting600 enrolled
NCT03470922 2025-09-09RELATIVITY-047Bristol-Myers SquibbPhase 2/3 Active not recruiting714 enrolled 17 charts 1 FDA